(Q40847554)

English

Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

0 references

coronary artery disease

1 reference

based on heuristic

inferred from title

author name string

Muls E

1

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Van Ganse E

2

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Closon MC

3

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 April 1998

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Atherosclerosis

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

137 Suppl

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

S111-6

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900321-3

7 January 2021

Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900321-3

7 January 2021

Gemfibrozil cost-benefit study. Targeting subgroups for effective hyperlipidaemia drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900321-3

7 January 2021

A model for evaluating the cost-effectiveness of cholesterol-lowering treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900321-3

7 January 2021

Cost and health implications of cholesterol lowering

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900321-3

7 January 2021

Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900321-3

7 January 2021

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II)

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900321-3

7 January 2021

Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900321-3

7 January 2021

Cost-effectiveness of captopril therapy after myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900321-3

7 January 2021

The Markov process in medical prognosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900321-3

7 January 2021

Long survival following myocardial infarction. Report on 255 patients living ten years or longer after the first attack

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900321-3

7 January 2021

Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900321-3

7 January 2021

Medical costs of coronary artery disease in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900321-3

7 January 2021

Did prognosis after acute myocardial infarction change during the past 30 years? A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900321-3

7 January 2021

A communitywide perspective of sex differences and temporal trends in the incidence and survival rates after acute myocardial infarction and out-of-hospital deaths caused by coronary heart disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900321-3

7 January 2021

Comparison of posthospital survival after acute myocardial infarction in women and men

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900321-3

7 January 2021

Prognosis after myocardial infarction: results of 15 year follow up

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900321-3

7 January 2021

Ten year mortality in patients with suspected acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900321-3

7 January 2021

Ten-year mortality among patients with suspected acute myocardial infarction in relation to early diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900321-3

7 January 2021

Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900321-3

7 January 2021

Cost-benefit analysis of lipid lowering therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900321-3

7 January 2021

Cost-effectiveness analysis of prenatal screening and vaccination against hepatitis B virus--the case of Belgium

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900321-3

7 January 2021

Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900321-3

7 January 2021

Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900321-3

7 January 2021

Cost-effectiveness analysis in heart disease, Part II: Preventive therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2897%2900321-3

7 January 2021

Identifiers

10.1016/S0021-9150(97)00321-3

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40847554&oldid=1908570386"